Benzinga - Although US stocks closed mixed on Monday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.
Vera Therapeutics
- The Trade: Vera Therapeutics, Inc. (NASDAQ: VERA) Director Beth Seidenberg acquired a total of 2,300 shares an average price of $7.24. To acquire these shares, it cost around $16.65 thousand.
- What’s Happening: Vera Therapeutics, during February, announced pricing of 14.28 million share public offering of Class A common stock at $7 per share.
- What Vera Therapeutics Does: Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases.
- The Trade: Beyond Air, Inc. (NASDAQ: XAIR) Director William P Forbes acquired a total of 5,000 shares at an average price of $6.67. To acquire these shares, it cost around $33.35 thousand.
- What’s Happening: Beyond Air posted a wider-than-expected Q3 loss.
- What Beyond Air Does: Beyond Air Inc is a clinical-stage medical device and biopharmaceutical company which develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Biomea Fusion
- The Trade: Biomea Fusion, Inc. (NASDAQ: BMEA) 10% owner Cormorant Asset Management LP bought a total of 400,000 shares at an average price of $30.00. To acquire these shares, it cost around $12 million.
- What’s Happening: Biomea Fusion announced pricing of upsized from $125 million to $150 million public offering of 5 million shares of common stock at a price of $30 per share.
- What Biomea Fusion Does: Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.